Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited)

v3.21.2
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited) - USD ($)
$ in Thousands
Series B Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 9 $ 226,524 $ (46) $ (217,070) $ 9,417
Balance, at beginning (in shares) at Dec. 31, 2019 8,531,504        
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share) $ 13 7,461 7,474
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share) (in shares)   13,111,999        
Deemed dividend in connection with repricing of November 2019 warrants 451 451
Warrant deemed dividend (451) (451)
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711) 4,602 4,602
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711) (in shares) 5,313          
Beneficial conversion feature in connection with issuance of Series B Convertible preferred stock 1,260 1,260
Preferred stock deemed dividend (1,260) (1,260)
Issuance of common stock and common stock warrants in February 2020 ($0.57 per share, net of transactional expenses $292) $ 4 1,891 1,895
Issuance of common stock and common stock warrants in February 2020 ($0.57 per share, net of transactional expenses of $292) (in shares)   3,837,000        
Issuance of common stock upon conversion of Series B Convertible preferred stock $ 9 (9)
Issuance of common stock upon conversion of Series B Convertible preferred stock (in shares) (5,313) 9,321,053        
Issuance of common stock in March 2020 ($1.10 per share, net of transactional expenses of $1,221) $ 14 14,770 14,784
Issuance of common stock in March 2020 ($1.10 per share, net of transactional expenses of $1,221) ( in shares)   14,550,000        
Employee stock purchase plan 2 2
Employee stock purchase plan (in shares)   1,578        
Stock-based compensation 360 360
Foreign currency translation gain (loss) (14) (14)
Net loss (7,273) (7,273)
Ending balance, value at Mar. 31, 2020 $ 49 255,601 (60) (224,343) 31,247
Balance, at end (in shares) at Mar. 31, 2020 49,353,134        
Beginning balance, value at Dec. 31, 2019 $ 9 226,524 (46) (217,070) 9,417
Balance, at beginning (in shares) at Dec. 31, 2019 8,531,504        
Preferred stock deemed dividend           (1,260)
Foreign currency translation gain (loss)           (18)
Net loss           (33,442)
Ending balance, value at Sep. 30, 2020 $ 140 313,004 (64) (250,512) 62,568
Balance, at end (in shares) at Sep. 30, 2020 140,159,546        
Beginning balance, value at Mar. 31, 2020 $ 49 255,601 (60) (224,343) 31,247
Balance, at beginning (in shares) at Mar. 31, 2020 49,353,134        
Issuance of common stock in June 2020 under the equity line $ 1 277 278
Issuance of common stock in June 2020 under the equity line (in shares)   464,471        
Issuance of common stock in May and June 2020 under At-the-market offering, net of transaction expenses of $1,131 $ 53 34,089 34,142
Issuance of common stock in May and June 2020 under At-the-market offering, net of transaction expenses of $1,131 (in shares)   52,986,301        
Issuance of common stock in the acquisition of Trigemina assets $ 2 1,358 1,360
Issuance of common stock in the acquisition of Trigemina assets (in shares)   2,000,000        
Stock-based compensation 733 733
Foreign currency translation gain (loss) (9) (9)
Net loss (14,179) (14,179)
Ending balance, value at Jun. 30, 2020 $ 105 292,058 (69) (238,522) 53,572
Balance, at end (in shares) at Jun. 30, 2020 104,803,906        
Preferred stock deemed dividend          
Issuance of common stock in July 2020, net of transaction expenses of $829 $ 21 9,620 9,641
Issuance of common stock in July 2020, net of transaction expenses of $829 (in shares)   20,940,000        
Issuance of common stock in September 2020 under At-the-market offering, net of transactional expenses of $267 $ 9 7,997 8,006
Issuance of common stock in September 2020 under At-the-market offering, net of transactional expenses of $267 (in shares)   9,282,236        
Issuance of common stock in exchange for exercise of warrants in July and August 2020 (see Note 9) $ 5 2,417 2,422
Issuance of common stock in exchange for exercise of warrants in July and August 2020 (see Note 9) (in shares)   4,533,404        
Issuance of commitment shares under 2020 Purchase Agreement
Issuance of commitment shares under 2020 Purchase Agreement (in shares)   600,000        
Stock-based compensation 912 912
Foreign currency translation gain (loss) 5 5
Net loss (11,990) (11,990)
Ending balance, value at Sep. 30, 2020 $ 140 313,004 (64) (250,512) 62,568
Balance, at end (in shares) at Sep. 30, 2020 140,159,546        
Beginning balance, value at Dec. 31, 2020 $ 206 355,037 (62) (267,533) 87,648
Balance, at beginning (in shares) at Dec. 31, 2020 206,008,683        
Issuance of common stock in exchange for exercise of warrants in March 2021 ($0.57 per share) 2 2
Issuance of common stock in exchange for exercise of warrants in March 2021 ($0.57 per share) (in shares)   3,400        
Issuance of common stock in January 2021 ($0.80 per share), net of transactional expenses of $3,096 $ 50 36,854 36,904
Issuance of common stock in January 2021 ($0.80 per share), net of transactional expenses of $3,096 (in shares)   50,000,000        
Issuance of common stock in February 2021 ($1.20 per share), net of transactional expenses of $5,002 $ 58 64,939 64,997
Issuance of common stock in February 2021 ($1.20 per share), net of transactional expenses of $5,002 (in shares)   58,333,334        
Issuance of common stock in January 2021 under At-the-market offering, net of transactional expenses of $230 $ 10 6,769 6,779
Issuance of common stock in January 2021 under At-the-market offering, net of transactional expenses of $230 (in shares)   9,517,867        
Employee stock purchase plan 28 28
Employee stock purchase plan (in shares)   54,447        
Stock-based compensation 1,212 1,212
Foreign currency translation gain (loss) (1) (1)
Net loss (20,653) (20,653)
Ending balance, value at Mar. 31, 2021 $ 324 464,841 (63) (288,186) 176,916
Balance, at end (in shares) at Mar. 31, 2021 323,917,731        
Beginning balance, value at Dec. 31, 2020 $ 206 355,037 (62) (267,533) 87,648
Balance, at beginning (in shares) at Dec. 31, 2020 206,008,683        
Preferred stock deemed dividend          
Foreign currency translation gain (loss)           (19)
Net loss           (62,734)
Ending balance, value at Sep. 30, 2021 $ 404 532,162 (81) (330,267) 202,218
Balance, at end (in shares) at Sep. 30, 2021 403,673,156        
Beginning balance, value at Mar. 31, 2021 $ 324 464,841 (63) (288,186) 176,916
Balance, at beginning (in shares) at Mar. 31, 2021 323,917,731        
Issuance of common stock in April and June 2021 under At-the-market offering, net of transactional expenses of $612 $ 16 18,686 18,702
Issuance of common stock in April and June 2021 under At-the-market offering, net of transactional expenses of $612 (in shares)   15,658,426        
Issuance of commitment shares under 2021 Purchase Agreement
Issuance of commitment shares under 2021 Purchase agreement (in shares)   1,280,000        
Issuance of common stock under 2021 Purchase Agreement $ 3 3,344 3,347
Issuance of common stock under 2021 Purchase agreement (in shares)   2,750,000        
Issuance of common stock in the acquisition of the OyaGen license $ 3 2,997 3,000
Issuance of common stock in the acquisition of the OyaGen license (in shares)   2,752,294        
Stock-based compensation 2,089 2,089
Foreign currency translation gain (loss) (8) (8)
Net loss (23,553) (23,553)
Ending balance, value at Jun. 30, 2021 $ 346 491,957 (71) (311,739) 180,493
Balance, at end (in shares) at Jun. 30, 2021 346,358,451        
Issuance of common stock in July, August and September 2021 under At-the-market offering, net of transactional expenses of $389 $ 17 11,711 11,728
Issuance of common stock in July, August and September 2021 under At-the-market offering, net of transactional expenses of $389 (in shares)   17,198,200        
Issuance of common stock under 2021 Purchase Agreement $ 40 26,125 26,165
Issuance of common stock under 2021 Purchase agreement (in shares)   40,000,000        
Preferred stock deemed dividend          
Employee stock purchase plan $ 1 67 68
Employee stock purchase plan (in shares)   116,505        
Stock-based compensation 2,302 2,302
Foreign currency translation gain (loss) (10) (10)
Net loss (18,528) (18,528)
Ending balance, value at Sep. 30, 2021 $ 404 $ 532,162 $ (81) $ (330,267) $ 202,218
Balance, at end (in shares) at Sep. 30, 2021 403,673,156